Literature DB >> 28595532

Pharmacological and Toxicological Profile of Harmane-β-Carboline Alkaloid: Friend or Foe.

Haroon Khan1, Seema Patel2, Mohammad A Kamal3.   

Abstract

BACKGROUND: The plant secondary metabolites have an outstanding therapeutic potential and success over the years. In fact, it is the foundation of numerous clinically used drugs. Similarly, these is a general perception that these products are inherent safety. However, such products might have toxic/unwanted lethal effects therefore, along with biological relevance, toxicological evaluation is equally important for clinical applications. Therefore, harmane- β-carboline alkaloid was investigated for both therapeutic and toxicological potential.
METHODS: The literature related to the therapeutic/toxicological effects of the alkaloid was searched using various scientific data bases including Google, ScienceDirect, PubMed, SpringerLink, ASC. The peer reviewed articles were only selected.
RESULTS: The harmane-β-carboline alkaloid has shown several pharmacological activities such as antianxiety, antidepressant, antiplatelet, antidiabetic, acetylcholinesterase and myeloperoxidase inhibition, antioxidant, antiparasitic, hypotensive, morphine withdrawal syndrome alleviation, and antinociceptive effects. On the other hand, it exhibited tremorogenic effect, for a symptom of Parkinson's disease. Adverse effect of the alkaloid on learning and memory have also been observed.
CONCLUSIONS: All together, it is, concluded in this review that harmane elicited marked pharmacological effects but simultaneously, it possessed some serious side effects that could be the primary hurdle in the way of its clinical testing. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Harmane-β-carboline alkaloid; neuropathology; parkinson's disease; pharmacokineticzzm321990profile; pharmacological effects; toxicological potential

Mesh:

Substances:

Year:  2017        PMID: 28595532     DOI: 10.2174/1389200218666170607100947

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  8 in total

1.  Identification of potential human urinary biomarkers for tomato juice intake by mass spectrometry-based metabolomics.

Authors:  Yannick Hövelmann; Annika Jagels; Robin Schmid; Florian Hübner; Hans-Ulrich Humpf
Journal:  Eur J Nutr       Date:  2019-02-28       Impact factor: 5.614

2.  Harmane Potentiates Nicotine Reinforcement Through MAO-A Inhibition at the Dose Related to Cigarette Smoking.

Authors:  Zheng Ding; Xiangyu Li; Huan Chen; Hongwei Hou; Qingyuan Hu
Journal:  Front Mol Neurosci       Date:  2022-06-27       Impact factor: 6.261

3.  Harmane ameliorates obesity though inhibiting lipid accumulation and inducing adipocyte browning.

Authors:  Yanwen Li; Chanjuan Li; Jiaqiang Wu; Wenfeng Liu; Dongli Li; Jun Xu
Journal:  RSC Adv       Date:  2020-01-27       Impact factor: 4.036

4.  Identification of a circRNA-miRNA-mRNA regulatory network for exploring novel therapeutic options for glioma.

Authors:  Yi He; Yihong Chen; Yuxin Tong; Wenyong Long; Qing Liu
Journal:  PeerJ       Date:  2021-08-06       Impact factor: 2.984

Review 5.  Alkaloids and Colon Cancer: Molecular Mechanisms and Therapeutic Implications for Cell Cycle Arrest.

Authors:  Haroon Khan; Waqas Alam; Khalaf F Alsharif; Michael Aschner; Samreen Pervez; Luciano Saso
Journal:  Molecules       Date:  2022-01-28       Impact factor: 4.411

Review 6.  β-Carboline-based molecular hybrids as anticancer agents: a brief sketch.

Authors:  Jay Prakash Soni; Yogesh Yeole; Nagula Shankaraiah
Journal:  RSC Med Chem       Date:  2021-03-24

7.  Effects of Natural Monoamine Oxidase Inhibitors on Anxiety-Like Behavior in Zebrafish.

Authors:  Oihane Jaka; Iñaki Iturria; Marco van der Toorn; Jorge Hurtado de Mendoza; Diogo A R S Latino; Ainhoa Alzualde; Manuel C Peitsch; Julia Hoeng; Kyoko Koshibu
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

8.  Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy.

Authors:  Katharina E Meijboom; Viola Volpato; Jimena Monzón-Sandoval; Joseph M Hoolachan; Suzan M Hammond; Frank Abendroth; Olivier G de Jong; Gareth Hazell; Nina Ahlskog; Matthew Ja Wood; Caleb Webber; Melissa Bowerman
Journal:  JCI Insight       Date:  2021-07-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.